Lymphocyte-derived cytokines in inflammatory arthritis

References

• Wong BR, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997; 272: 25190–25194
   PubMed Web of Science ®Google Scholar
• Yasuda H, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597–3602
   PubMed Web of Science ®Google Scholar
• Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–176
   PubMed Web of Science ®Google Scholar
• Horwood NJ, et al. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999; 265: 144–150
   PubMed Web of Science ®Google Scholar
• Kong YY, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304–309
   PubMed Web of Science ®Google Scholar
• Kong YY, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315–323
   PubMed Web of Science ®Google Scholar
• Shinoda K, et al. Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes. Bone 2003; 33: 711–720
   Google Scholar
• Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005; 208: 154–168
   PubMed Web of Science ®Google Scholar
• Sinigaglia L, Varenna M, Girasole G, Bianchi G. Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 2006; 32: 631–658
   PubMed Web of Science ®Google Scholar
• Feldmann M, et al. Anti-TNF therapy: Where have we got to in 2005?. J Autoimmun 2005; 25(Suppl)26–28
   Google Scholar
• Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 1982; 79: 3632–3636
   PubMed Web of Science ®Google Scholar
• Ranges GE, Sriram S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985; 162: 1105–1110
   PubMed Web of Science ®Google Scholar
• Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: New subsets and new targets. Curr Opin Rheumatol 2007; 19: 284–288
   PubMed Web of Science ®Google Scholar
• Ernst CW, et al. Diminished forkhead box P3/CD25 double-positive T regulatory cells are associated with the increased nuclear factor-kappaB ligand (RANKL+) T cells in bone resorption lesion of periodontal disease. Clin Exp Immunol 2007; 148: 271–280
   Web of Science ®Google Scholar
• Kim YG, et al. Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem Biophys Res Commun 2007; 357: 1046–1052
   Web of Science ®Google Scholar
• Young N, Mikhalkevich N, Yan Y, Chen D, Zheng WP. Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma. J Immunol 2005; 175: 8287–8295
   PubMed Web of Science ®Google Scholar
• Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998; 139: 4743–4746
   PubMedGoogle Scholar
• Geusens PP, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54: 1772–1777
   PubMed Web of Science ®Google Scholar
• Li Y, et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007; 109: 3839–3848
   PubMed Web of Science ®Google Scholar
• Schett G, et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003; 48: 2042–2051
   PubMed Web of Science ®Google Scholar
• Romas E, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002; 161: 1419–1427
   PubMed Web of Science ®Google Scholar
• Lam J, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481–1488
   PubMed Web of Science ®Google Scholar
• Redlich K, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46: 785–792
   PubMed Web of Science ®Google Scholar
• Chen YF, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10: 1–229, iii–iv, xi–xiii
   Web of Science ®Google Scholar
• Kaneki H, et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 2006; 281: 4326–4333
   PubMedGoogle Scholar
• Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282–290
   PubMed Web of Science ®Google Scholar
• Rannou F, Francois M, Corvol MT, Berenbaum F. Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine 2006; 73: 29–36
   PubMed Web of Science ®Google Scholar
• Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv Ther 2006; 23: 208–217
   PubMed Web of Science ®Google Scholar
• Zwerina J, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50: 277–290
   PubMed Web of Science ®Google Scholar
• Kurihara N, Roodman GD. Interferons-alpha and -gamma inhibit interleukin-1 beta-stimulated osteoclast-like cell formation in long-term human marrow cultures. J Interferon Res 1990; 10: 541–547
   Google Scholar
• Boissier MC, et al. Biphasic effect of interferon-gamma in murine collagen-induced arthritis. Eur J Immunol 1995; 25: 1184–1190
   PubMed Web of Science ®Google Scholar
• Gao Y, et al. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 2007; 117: 122–132
   PubMed Web of Science ®Google Scholar
• Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): Requirement for GM-CSF in the effector phase of disease. Arthritis Res 2001; 3: 293–298
   PubMedGoogle Scholar
• Hodge JM, et al. Osteoclastic potential of human CFU-GM: Biphasic effect of GM-CSF. J Bone Miner Res 2004; 19: 190–199
   Google Scholar
• Horwood NJ, Elliott J, Martin TJ, Gillespie MT. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001; 166: 4915–4921
   PubMed Web of Science ®Google Scholar
• Bombardieri M, McInnes IB, Pitzalis C. Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. Expert Opin Biol Ther 2007; 7: 31–40
   PubMed Web of Science ®Google Scholar
• Quinn JM, et al. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res 2001; 16: 1787–1794
   PubMed Web of Science ®Google Scholar
• Mendez-Davila C, Garcia-Moreno C, Turbi C, de la Piedra C. Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures. J Endocrinol Invest 2004; 27: 904–912
   Google Scholar
• Koenders MI, et al. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9 and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum 2005; 52: 3239–3247
   PubMed Web of Science ®Google Scholar
• Kotake S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345–1352
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Res Ther 2005; 7: 29–37
   PubMed Web of Science ®Google Scholar
• Koenders MI, et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006; 176: 6262–6269
   PubMed Web of Science ®Google Scholar
• Ogata Y, et al. A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2. J Immunol 1999; 162: 2754–2760
   PubMed Web of Science ®Google Scholar
• Harada S, et al. Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 1508–1516
   PubMed Web of Science ®Google Scholar
• Baslund B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: A proof-of-concept study. Arthritis Rheum 2005; 52: 2686–2692
   PubMed Web of Science ®Google Scholar
• Mirosavljevic D, et al. T-cells mediate an inhibitory effect of interleukin-4 on osteoclastogenesis. J Bone Miner Res 2003; 18: 984–993
   PubMedGoogle Scholar
• Yamada A, et al. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology 2007; 120: 573–579
   Google Scholar
• Lubberts E, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000; 105: 1697–1710
   PubMed Web of Science ®Google Scholar
• Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 2002; 169: 3353–3362
   PubMed Web of Science ®Google Scholar
• Plater-Zyberk C, et al. Amelioration of arthritis in two murine models using antibodies to oncostatin M. Arthritis Rheum 2001; 44: 2697–2702
   PubMed Web of Science ®Google Scholar
• Smolen JS, Maini RN. Interleukin-6: A new therapeutic target. Arthritis Res Ther 2006; 8(Suppl 2)S5
   Google Scholar
• Hartgring SA, Bijlsma JW, Lafeber FP, van Roon JA. Interleukin-7 induced immunopathology in arthritis. Ann Rheum Dis 2006; 65(Suppl 3)iii69–74
   PubMedGoogle Scholar
• Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 2003; 100: 125–130
   PubMed Web of Science ®Google Scholar
• Weitzmann MN, Roggia C, Toraldo G, Weitzmann L, Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002; 110: 1643–1650
   PubMed Web of Science ®Google Scholar
• Ryan MR, et al. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA 2005; 102: 16735–16740
   Google Scholar
• Xu LX, et al. Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. J Cell Physiol 1995; 165: 624–629
   Google Scholar
• Evans KE, Fox SW. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol 2007; 8: 4
   PubMed Web of Science ®Google Scholar
• Liu D, Yao S, Wise GE. Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle. Eur J Oral Sci 2006; 114: 42–49
   Web of Science ®Google Scholar
• Hsu YH, et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 2006; 54: 2722–2733
   PubMed Web of Science ®Google Scholar
• Ikeuchi H, et al. Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum 2005; 52: 1037–1046
   PubMed Web of Science ®Google Scholar
• Joosten LA, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006; 103: 3298–3303
   PubMed Web of Science ®Google Scholar